US 12,076,372 B2
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
Sherry Bullens, Novato, CA (US); Stuart Bunting, Novato, CA (US); Tianwei Chou, Novato, CA (US); Augustus O. Okhamafe, Concord, CA (US); Christopher P. Price, Aachen (DE); Daniel J. Wendt, Novato, CA (US); and Clarence Yap, Novato, CA (US)
Assigned to BIOMARIN PHARMACEUTICAL INC., Novato, CA (US)
Filed by BIOMARIN PHARMACEUTICAL INC., Novato, CA (US)
Filed on Jan. 20, 2023, as Appl. No. 18/157,573.
Application 15/880,002 is a division of application No. 15/225,355, filed on Aug. 1, 2016, granted, now 9,907,834, issued on Mar. 6, 2018.
Application 18/157,573 is a continuation of application No. 16/837,910, filed on Apr. 1, 2020, granted, now 11,590,204.
Application 16/837,910 is a continuation of application No. 15/880,002, filed on Jan. 25, 2018, granted, now 10,646,550, issued on May 12, 2020.
Claims priority of provisional application 62/320,704, filed on Apr. 11, 2016.
Claims priority of provisional application 62/199,081, filed on Jul. 30, 2015.
Prior Publication US 2023/0293637 A1, Sep. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/22 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 38/00 (2006.01); A61K 38/16 (2006.01); A61K 38/17 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/18 (2017.01); A61K 47/20 (2006.01); A61K 47/26 (2006.01)
CPC A61K 38/2242 (2013.01) [A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 38/1709 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01); A61K 47/20 (2013.01); A61K 47/26 (2013.01)] 16 Claims
 
1. A method of treating hypochondroplasia in a subject in need thereof comprising the step of administering to said subject a composition comprising a C-type natriuretic peptide (CNP) variant in an amount of at least 7.5 μg/kg of said CNP variant peptide, wherein the CNP variant is selected from the group consisting of:
QEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC (SEQ ID NO: 1);
MQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (SEQ ID NO: 2);
PQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (SEQ ID NO: 3);
GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC (SEQ ID NO: 4);
PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (SEQ ID NO: 5);
MGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (SEQ ID NO: 6); and
GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (SEQ ID NO: 7), wherein the CNP variant is in a formulation comprising citric acid monohydrate, sodium citrate dihydrate, trehalose dihydrate, D-mannitol, L-methionine and polysorbate 80 and wherein the step of administering treats said hypochondroplasia.